Participation of clinical pharmacist specialized in oncology in the treatment of a patient with advanced esophageal carcinoma complicated with hypertension: one case report

doi:10.5246/jcps.2014.05.046

Journal of Chinese Pharmaceutical Sciences ›› 2014, Vol. 23 ›› Issue (5): 330-334.DOI: 10.5246/jcps.2014.05.046

• Short communications • Previous Articles Next Articles

Participation of clinical pharmacist specialized in oncology in the treatment of a patient with advanced esophageal carcinoma complicated with hypertension: one case report

Zeng Wang¹, Haiying Ding¹, Meiqin Yuan², Nengming Lin^1,3*

1. Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou 310022, China
2. Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China
3. Institute for Individualized Medicine, Hangzhou First People’s Hospital, Hangzhou 310006, China

Received:2014-01-08 Revised:2014-02-13 Online:2014-05-23 Published:2014-02-24
Contact: Tel.: 86-571-88122438; Fax: 86-571-88122202; E-mail: lnm1013@163.com

Abstract

Abstract:

Clinical pharmacists specialized in oncology contributed to the safe and effective chemotherapy treatment for advanced esophageal carcinoma patients complicated with hypertension by participating in medication practice. Optimal therapeutic regimen was proposed, and pharmaceutical care and health education were provided based on the condition of each patient. By providing pharmaceutical care for cancer patients with their pharmacy knowledge, clinical pharmacists specialized in oncology can not only reduce the potential risks of chemotherapy, but also take into account of other accompanying diseases, thus improving the comprehensive treatment of patients. Furthermore, it deepened the understanding of the role of clinical pharmacy practice by patients and other medical workers. Involvement of clinical pharmacist in therapeutic practice could improve the outcome of pharmacotherapy.

CLC Number:

R954

Supporting:

Zeng Wang, Haiying Ding, Meiqin Yuan, Nengming Lin. Participation of clinical pharmacist specialized in oncology in the treatment of a patient with advanced esophageal carcinoma complicated with hypertension: one case report[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(5): 330-334.

[1]	Zhiyong Dong, Xiantu Qiu, Stacy A. Kujawa, S.M. Shariful Islam, Jie Zhang. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 264-275.
[2]	Min Chen, Feng Jiang, Ming Zheng, Limei Yang, Hongjin Gao. Design and implementation of mobile APP for medication guidance related to pharmacogenomic based on APICloud platform [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 276-283.
[3]	Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202.
[4]	Xinpu Lu, Zhigang Guo, Mengyuan Fu, Haishaerjiang Wushouer, Luwen Shi, Xiaodong Guan. The impacts of national essential medicine policies on the rational use of medicines in China: A cross-sectional study in primary health care institution [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 49-55.
[5]	Chao Zhang, Ruohan Xie, Chuhui Wang, Chenchen Xi, Mengjia Ge. Dose optimization of piperacillin/tazobactam in patients with renal dysfunction based on population pharmacokinetic and pharmacodynamic simulations [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(12): 824-831.
[6]	Xiaodong Guan, Lili Ma, Guoying Wang, Haishaerjiang Wushouer, Chunxia Man, Sheng Han, Luwen Shi. An analysis on the factors associated with reuse of insulin pen needles in type 2 diabetic patients in China [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(1): 51-58.
[7]	Zhou Linguang, Jiang Bin. Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(1): 59-63.
[8]	Dehua Zhao, Mingming Chu, Jing Chen, Jisheng Wang. Meta-analysis of gemcitabine at 30 min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 763-770.
[9]	Tong Cai, Yusheng Pei, Guolai Zhang, Chen Chen, Hua Gao. Establishment of the 8th National Standard of Endotoxin [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 771-774.
[10]	Liqun Wang, Xiaohui Xie, Ruirui Zhou. Assessment of the quality of randomized controlled trials on pharmaceutical care for asthmatic patients in journals of mainland China [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(3): 212-221.
[11]	Jieying Lin, Jingjing Liu, Yaning Qi, Chunming Wang. Analyzing the risk of drug abuse for morphine-containing Chinese patent medicines in China [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(2): 139-146.
[12]	Ru Han, Yajing An, Rongsheng Zhao. Additive effect of α-ketoacids in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(1): 63-75.
[13]	Yuanyuan Liu, Shuyao Liang, Ken Chen, Fan Zhang, Fang Liu. Influence of voriconazole on pharmacokinetics and safety of combined drugs: a systematic review [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 785-798.
[14]	Mostafa Essam Eissa. Study of parameters affecting infection risk from contaminated injectable products using multiple spot contamination model: a case study of insulin vials [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 832-837.
[15]	Xiaoyan Nie, Yang Xu, Yu Fu, Junlei Li, Guangkai Liang, Yong Zhang, Yun Lu, Jian Liu, Luwen Shi. The correlation and consistency of light transmission aggregometry and thrombelastography in identifying high clopidogrel on-treatment platelet reactivity in patients with acute coronary syndrome [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 838-845.

Participation of clinical pharmacist specialized in oncology in the treatment of a patient with advanced esophageal carcinoma complicated with hypertension: one case report

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments